Momenta Pharmaceuticals, Inc. (MNTA)

[Double_Bagel]

Barclays sets CHRS target value at $46 ($1.8 Billion valuation) and MNTA target value at $22 ($1.5 Billion valuation). So, he gives almost no credit for MNTA's biosimilar platform.

http://www.theflyonthewall.com/permalinks/entry.php?symbol=chrs
Coherus Biosciences initiated with an Overweight at Barclays
Barclays analyst Douglas Tsao started Coherus Biosciences with an Overweight rating saying the company's exclusive focus on biosimilars should allow it to "navigate the patent landscape nimbly" and meet the "high bar" for U.S. approval with label extrapolation. The analyst put a $46 price target on the stock.

http://www.theflyonthewall.com/permalinks/entry.php/MNTAid1549747/MNTA-Momenta-Pharma-to-host-conference-call
Momenta initiated with an Equal Weight at Barclays
Barclays analyst Douglas Tsao started Momenta Pharmaceuticals with an Equal Weight rating saying the stock is likely to trade on Glatopa adoption, which he feels is unlikely to hit inflection in the near term. The analyst has a $22 price target for shares.